In this study, we aimed to investigate the molecular mechanism underlying acquired resistance to DZNep in B-cell lymphoma, and to identify biomarkers predictive of the therapeutic success of EZH2 inhibition with DZNep. Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.